SINGULAR GENOMICS SYSTEMS IN (OMIC)
US82933R3084 - Common Stock
OMIC gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 56 industry peers in the Life Sciences Tools & Services industry. OMIC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, OMIC is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
OMIC had negative earnings in the past year.
OMIC had a negative operating cash flow in the past year.
In the past 5 years OMIC always reported negative net income.
In the past 5 years OMIC always reported negative operating cash flow.
1.2 Ratios
OMIC has a worse Return On Assets (-46.27%) than 87.50% of its industry peers.
Looking at the Return On Equity, with a value of -70.04%, OMIC is doing worse than 73.21% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -46.27% | ||
| ROE | -70.04% | ||
| ROIC | N/A |
ROA(3y)-30.4%
ROA(5y)-41.68%
ROE(3y)-39.09%
ROE(5y)-60.75%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for OMIC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
OMIC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for OMIC has been reduced compared to 1 year ago.
Compared to 1 year ago, OMIC has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -3.45, we must say that OMIC is in the distress zone and has some risk of bankruptcy.
OMIC has a Altman-Z score of -3.45. This is amonst the worse of the industry: OMIC underperforms 91.07% of its industry peers.
A Debt/Equity ratio of 0.04 indicates that OMIC is not too dependend on debt financing.
OMIC's Debt to Equity ratio of 0.04 is fine compared to the rest of the industry. OMIC outperforms 69.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.45 |
ROIC/WACCN/A
WACC12.04%
2.3 Liquidity
OMIC has a Current Ratio of 7.37. This indicates that OMIC is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 7.37, OMIC belongs to the top of the industry, outperforming 83.93% of the companies in the same industry.
OMIC has a Quick Ratio of 6.67. This indicates that OMIC is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 6.67, OMIC belongs to the best of the industry, outperforming 83.93% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.37 | ||
| Quick Ratio | 6.67 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 8.62% over the past year.
Looking at the last year, OMIC shows a small growth in Revenue. The Revenue has grown by 2.54% in the last year.
EPS 1Y (TTM)8.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.74%
Revenue 1Y (TTM)2.54%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-12.12%
3.2 Future
The Earnings Per Share is expected to grow by 9.55% on average over the next years. This is quite good.
Based on estimates for the next years, OMIC will show a very strong growth in Revenue. The Revenue will grow by 108.52% on average per year.
EPS Next Y11.07%
EPS Next 2Y8.56%
EPS Next 3Y9.55%
EPS Next 5YN/A
Revenue Next Year13.37%
Revenue Next 2Y96.92%
Revenue Next 3Y108.52%
Revenue Next 5YN/A
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
OMIC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OMIC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.56%
EPS Next 3Y9.55%
5. Dividend
5.1 Amount
OMIC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SINGULAR GENOMICS SYSTEMS IN
NASDAQ:OMIC (12/20/2024, 8:00:02 PM)
19.55
-0.39 (-1.96%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners51%
Inst Owner Change58.18%
Ins Owners13.96%
Ins Owner Change0.11%
Market Cap49.07M
Analysts80
Price Target12.7 (-35.04%)
Short Float %2.9%
Short Ratio2.77
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.66%
Min EPS beat(2)5.17%
Max EPS beat(2)18.16%
EPS beat(4)4
Avg EPS beat(4)9.18%
Min EPS beat(4)4.76%
Max EPS beat(4)18.16%
EPS beat(8)8
Avg EPS beat(8)13.23%
EPS beat(12)12
Avg EPS beat(12)13.65%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)14.44%
Min Revenue beat(2)-51.75%
Max Revenue beat(2)80.64%
Revenue beat(4)3
Avg Revenue beat(4)20.95%
Min Revenue beat(4)-51.75%
Max Revenue beat(4)80.64%
Revenue beat(8)3
Avg Revenue beat(8)-8.77%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)31.4%
PT rev (3m)91.54%
EPS NQ rev (1m)0.5%
EPS NQ rev (3m)-2748.21%
EPS NY rev (1m)1.55%
EPS NY rev (3m)1.51%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)37.31%
Revenue NY rev (1m)-5.82%
Revenue NY rev (3m)-5.85%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 18.41 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.4 | ||
| P/tB | 0.4 | ||
| EV/EBITDA | N/A |
EPS(TTM)-35.09
EYN/A
EPS(NY)-32.28
Fwd EYN/A
FCF(TTM)-32.21
FCFYN/A
OCF(TTM)-32.04
OCFYN/A
SpS1.06
BVpS49.1
TBVpS49.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -46.27% | ||
| ROE | -70.04% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-30.4%
ROA(5y)-41.68%
ROE(3y)-39.09%
ROE(5y)-60.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 10.24% | ||
| Cap/Sales | 15.87% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.37 | ||
| Quick Ratio | 6.67 | ||
| Altman-Z | -3.45 |
F-Score3
WACC12.04%
ROIC/WACCN/A
Cap/Depr(3y)235.15%
Cap/Depr(5y)229.93%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.74%
EPS Next Y11.07%
EPS Next 2Y8.56%
EPS Next 3Y9.55%
EPS Next 5YN/A
Revenue 1Y (TTM)2.54%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-12.12%
Revenue Next Year13.37%
Revenue Next 2Y96.92%
Revenue Next 3Y108.52%
Revenue Next 5YN/A
EBIT growth 1Y5.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year10.37%
EBIT Next 3Y3.93%
EBIT Next 5YN/A
FCF growth 1Y9.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.96%
OCF growth 3YN/A
OCF growth 5YN/A